Abstract: Disclosed herein are degradable materials comprising the reaction product of an oxanorbornadiene crosslinker or derivative thereof and a multivalent nucleophile-terminated compound, wherein the reaction product is a degradable elastic solid capable of entraining cargo. Also disclosed herein are degradable materials comprising a polymeric and hyperbranched crosslinked material made with oxanorbornadiene linkage that can be activated for cleavage at a predetermined rate by addition of a nucleophile. Also disclosed herein are methods of making and using the same.

Abstract: A composition comprising: a benefit agent; at least one polymer including a polycaprolactone polymer; at least one lower alcohol; and at least one co-solvent; and a method for enhancing topical delivery of a benefit agent is disclosed.

Abstract: Film products, especially suitable for oral delivery, which can be formed during manufacture in the form of large and/or heavy film strips or sheets and subsequently cut into uniform dosage units, each dosage unit being uniform in content and having distributed therein a linear polysaccharide, such as pullulan, a plasticizer, and an active component.

Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.

Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of arteriosclerosis, hypertension, sickle-cell anemia, or other conditions. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: A dye-drug conjugate for preventing, treating, or imaging cancer having the following structure: wherein R1 and R2 are independently selected from the group consisting of —H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, —SO3H, —PO3H, —OH, —NH2, and -halogen; wherein Y1 and Y2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ?-alkylaminium, ?-alkynyl, PEGyl, PEGylcarboxylate, ?-PEGylaminium, ?-acyl-NH, ?-acyl-lysinyl-, ?-acyl-triazole, ?-PEGylcarboxyl-NH—, ?-PEGylcarboxyl-lysinyl, and ?-PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH2, SH and OH; and R3 and R4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the ima

Abstract: Methods for producing polypeptide-polymer conjugates include attachment of an initiator agent to a polypeptide specifically at the C-terminus of the polypeptide using a sortase enzyme and in situ polymerization of a polymer from the C-terminus. The polypeptide-polymer conjugates may have desirable pharmacological properties and may be used therapeutically.

Abstract: The present invention relates to polymer particles comprising antibiotics which are deliverable in situ, as well as a method of preparation thereof. The present invention also relates to bioactive biomaterials for the controlled delivery of antibiotics comprising support materials having such polymer particles on their surface. The invention also relates to implants, prostheses, stents, lenses or cements as well as any pharmaceutical composition comprising said biomaterials.

Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.

Abstract: The present invention provides a polypeptide complex on the basis of Titin-Telethonin beta-pleated sheet structure as a polypeptide or protein drug carrier, a method of using the polypeptide complex, and a fusion protein complex thereof. The polypeptide complex is capable of maintaining the activity of polypeptide or protein drugs and prolonging the half-life period simultaneously.

Abstract: Described herein are drug delivery conjugates for targeted therapy. In particular, described herein are drug delivery conjugates that include polyvalent linkers comprising one or more unnatural amino acids that are useful for treating cancers and inflammatory diseases.

Abstract: The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

Abstract: The present invention relates to biomolecule conjugates which comprise a biomolecule wherein at least one non-natural amino acid (NNAA) is integral to the structure of the biomolecule and wherein the NNAA is a point of attachment of a linker to which a payload, particularly a cytotoxic agent, is attached. More specifically, this invention relates to conjugates of cell-binding agents and active release products comprising cytotoxic agents wherein the conjugates are produced by means of a cycloaddition reaction. Methods of production, pharmaceutical compositions and methods of use are provided.

Abstract: The present invention relates to an anthracycline (PNU) derivative conjugate comprising a derivative of the anthracycline PNU-159682 having the formula (i) or formula (ii) which further comprises a linker structure X-L1-L2-L3-Y.

Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (1ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.

Abstract: The invention relates to chemical compounds and complexes that can be used in therapeutic and diagnostic applications.

Abstract: The present invention concerns a method for the treatment of recessive Catecholaminergic Polymorphic Ventricular Tachycardia comprising delivering a gene into a cardiac cell.

Abstract: The present invention relates to the use of NS1/2 region of murine norovirus MNV or a corresponding region from a member of the Caliciviridae family or a protein encoded by any one of those regions, for treating dysbiosis, immune system dysregulation and various disorders, as well as for enhancing mucosal integrity and stimulating IFN-induced genes.

Abstract: Poly(amine-co-ester-co-ortho ester) polymers, methods of forming active agent-load nanoparticles therefrom, and methods of using the nanoparticles for drug delivery are disclosed. The nanoparticles can be coated with an agent that reduces surface charge, an agent that increases cell-specific targeting, or a combination thereof. Typically, the loaded nanoparticles are less toxic, more efficient at drug delivery, or a combination thereof compared to a control or other transfection reagents.

Abstract: The invention relates to chimeric AAV capsids targeted to the central nervous system, virus vectors comprising the same, and methods of using the vectors to target the central nervous system. The invention further relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

Abstract: This invention presents a sequence of the virus AAV/XBP1s-HA, method and its use in the improvement of cognitive functions, of memory and of learning, as presented in the in vivo studies in FIG. 12/17 right panel.

Abstract: The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.

Abstract: The invention provides in vivo methods for identifying cancer-associated immunotherapy targets.

Abstract: The invention concerns the use of pyridinium furosemide or one of the derivatives, analogues, salts, metabolites, or prodrugs thereof in the preparation of a chemical model of a neurodegenerative disease, preferably Parkinson's disease. The invention also concerns the corresponding chemical model and the uses of same, in particular in screening tests for identifying drug candidates.

Abstract: An immuno-therapy for treatment of a tumor is provided. An effective dose of a composition containing a low dose of superparamagnetic iron oxide nanoparticle is administered to a tumor. Once the composition has been administered, it is recommended to avoid any means that would cause direct cytotoxic effects to the cancer cells and to normal/healthy tissue. The combination of composition-administered cancer cells with the avoidance of direct cytotoxic effects has been shown to be successful to inhibit the growth of the cancer cells or result in aptosis of the cancer cells. Additional dose(s) can be administered when it is determined that: (i) the tumor starts to grow and/or (ii) the remaining composition falls below a threshold. The immuno-therapy method is a safe, clinically applicable, ready-to-use theranostic approach for cancer patients who are unable to start chemoradiotherapy in a timely manner, i.e. an effective interim or adjunctive treatment for patients.

Abstract: The invention provides improved compositions relating to lipid-encapsulated gas microspheres and methods of their use.

Abstract: Disclosed herein are collagen-targeted imaging agents for positron emission tomography and related imaging methods using the collagen-targeted imaging agents. The collagen-targeted imaging agent is a cyclic polypeptide comprising a cyclic main body, wherein the cyclic main body comprises at least one S—S bond; at least two branches, wherein each of the at least two branches comprises at least three amino acids; and a linker, wherein the linker is capable of linking an imaging reporter.

Abstract: Provided are radiopaque compositions comprising one or more of yttrium (Y), strontium (Sr), gallium (Ga), and silicon, or oxides and salts thereof. The composition can comprise a combination of Y2O3, SrCO3, Ga2O3, and SiO2, and optionally MnO2, and TiO2. Other compositions comprise SrCO3, Ga2O3, TiO2, MnO2, and SiO2. The composition can be a particulate material. The compositions are useful for radioembolization to treat tumors.

Abstract: A method for removing microorganisms from liquid samples and a nanofiber containing liquid filtration medium that simultaneously exhibits high liquid permeability and high microorganism retention. Microorganisms such as bacteria, particularly B. Diminuta, are removed from a liquid by passing the liquid through a porous nanofiber containing filtration medium having a B. Diminuta LRV greater than about 9, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. Another method for removing microorganisms such as bacteria and Mycloplasma, includes passing the liquid through a porous nanofiber containing filtration medium having a microorganism LRV greater than about 8, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. The filtration medium can be in the form of a fibrous electro spun polymeric nanofiber liquid filtration medium mat.

Abstract: A method for removing microorganisms from liquid samples and a nanofiber containing liquid filtration medium that simultaneously exhibits high liquid permeability and high microorganism retention. Microorganisms such as bacteria, particularly B. Diminuta, are removed from a liquid by passing the liquid through a porous nanofiber containing filtration medium having a B. Diminuta LRV greater than about 9, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. Another method for removing microorganisms such as bacteria and Mycloplasma, includes passing the liquid through a porous nanofiber containing filtration medium having a microorganism LRV greater than about 8, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. The filtration medium can be in the form of a fibrous electro spun polymeric nanofiber liquid filtration medium mat.

Abstract: A method for removing microorganisms from liquid samples and a nanofiber containing liquid filtration medium that simultaneously exhibits high liquid permeability and high microorganism retention. Microorganisms such as bacteria, particularly B. Diminuta, are removed from a liquid by passing the liquid through a porous nanofiber containing filtration medium having a B. Diminuta LRV greater than about 9, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. Another method for removing microorganisms such as bacteria and Mycloplasma, includes passing the liquid through a porous nanofiber containing filtration medium having a microorganism LRV greater than about 8, and the nanofiber(s) has a diameter from about 10 nm to about 1,000 nm. The filtration medium can be in the form of a fibrous electro spun polymeric nanofiber liquid filtration medium mat.

Abstract: A multi-functional cutlery sterilizer, having a heating panel and a heating tube, operable via a press button panel of a main control device, so that the sterilization chamber can reach a high temperature to achieve sterilization. Also, a UV sterilization device is provided; by placing cutlery in the sterilization chamber and operating the UV sterilization device via the press button panel, UV light will illuminate and achieve UV sterilization. The cutlery sterilizer is additionally provided with UV sterilization, thereby providing an additional means for sterilization and thus equipping itself with more powerful functions. The sterilizer can sterilize cutlery made of different materials and therefore has a wider applicability. Further, cutlery not suitable for high temperature sterilization can be sterilized by UV sterilization.

Abstract: The present invention relates to an electrochemical device for releasing ions, comprising an electrical circuit comprising a first electrode and a second electrode adapted for providing a galvanic cell when the electrodes are exposed to a fluid constituting an electrolyte, and a boost converter adapted for amplifying a potential generated between the first and the second electrode. The electrical circuit further comprises a third electrode connected with an output side of the boost converter, wherein the second and the third electrode constitutes an electrolytic cell powered by the galvanic cell when the electrodes are exposed to a fluid. The present invention further relates to devices, such as a toothbrush or a shaver, adapted for being used in connection with a fluid, comprising such electrochemical device for releasing ions.

Abstract: Example plasmaclave devices are shown for using a plasma to sterilize objects or equipment (e.g., medical instruments, surgical devices, food preparation utensils, etc.) placed inside the plasmaclave devices. In some embodiments, the plasmaclave device includes fixed magnets, steering coils, and a high voltage electrode for generating a plasma field and controlling where the plasma field is focused, so that the plasma field is rapidly scanned over a target surface. In some embodiments, the plasmaclave device includes a high voltage coil, a motor, and a blade electrode for generating a plasma field and spinning the blade electrode, so that the plasma field is rapidly scanned over a target surface.

Abstract: Sterilization containers, components, and methods thereof. A locking mechanism is used to secure and release a filter assembly on a sterilization container includes two opposing buttons that, when compressed toward each other, unlock the locking mechanism and, when released, secure the locking mechanism.

Abstract: A closure for a medical sterile container having a trough-like first container part and a lid-type second container part includes a closure flap which can be arranged on one of the container parts so as to be able to pivot between a closed position, in which the container parts are interlocked with each other by the closure, and an open position in which the container parts are unlocked. The closure includes a latch element which in the closed position of the closure interlocks the closure flap with the other container part.

Abstract: Methods are provided that include positioning a disinfection apparatus in proximity to a cabinet, wherein the disinfection apparatus has a base supporting a germicidal source and the base includes components operationally coupled to the germicidal source for operating the germicidal source. The method further includes inserting the germicidal source into the cabinet such that at least a portion of the base is retained exterior to the cabinet and is operationally coupled to the germicidal source. Moreover, the method includes placing one or more items into the cabinet, closing the cabinet with the germicidal source and the one or more items in the cabinet and the base of the disinfection apparatus exterior to the cabinet, and then subsequently starting the disinfection source such that the germicidal source emits a germicide into the cabinet. Systems and cabinets used to conduct the aforementioned methods are also provided.

Abstract: A freshening product is provided.

Abstract: A system for releasing edible material is disclosed. The system comprises: a plurality of compartments adapted to receive a respective plurality of capsules, each capsule containing therein an edible material; a dispenser system configured for dispensing into an environment a fluid obtained from at least one edible material; and a controller configured for receiving data pertaining to a selection of at least two of the compartments and for signaling the dispenser system to dispense fluids obtained from edible materials contained in capsules of the selected compartments.

Abstract: A scent delivery system includes a housing that releases a volatile substance from a porous body into the air. The housing may be part of a scent dispersion device that includes volatilization as directed by a fan and a controller within the housing.

Abstract: A system for releasing flavor is disclosed. The system comprises: a plurality of compartments adapted to receive a respective plurality of capsules, each capsule containing therein a flavor material; a dispenser system configured for dispensing into an environment a fluid obtained from at least one flavor material; and a controller configured for receiving data pertaining to a selection of at least two of the compartments and for signaling the dispenser system to dispense fluids obtained from flavor materials contained in capsules of the selected compartments.

Abstract: The invention provides compositions based on an effective amount of an active anti-inflammatory ingredient of mineral solids fortified with methylglyoxal antibacterial activity for the treatment of wounds; and methods of treating a wound, comprising contacting a wound with the above compositions or a wound dressing containing the above compositions.

Abstract: An absorbent article includes a chassis comprising a topsheet, a backsheet, and an absorbent core disposed between the topsheet and backsheet. The absorbent core contains superabsorbent polymer material and about 10% or less by weight of cellulosic fibers. The backsheet comprises a film comprising a plurality of micropores. The film comprises odor absorbing material disposed in one or more of the micropores.

Abstract: The current invention concerns a multi-layer adhesive tape to compress and contract one or more scars, comprising: a top layer; a bonding layer adjacent to said top layer; a bottom layer adjacent to said bonding layer and opposite to said top layer; an adhesive layer adjacent to said flexible bottom layer and opposite to said bonding layer; and a first peelable liner at least adjacent to said adhesive layer and opposite to said bottom layer, wherein the widths of said top layer and bonding layer are larger than the widths of said bottom layer and adhesive layer, and wherein said adhesive layer comprises a rubber- or acrylic-based pressure-sensitive adhesive. The invention further concerns a multi-layer adhesive tape to compress and contract one or more scars, wherein said top layer has a thickness between 20 and 1100 ?m.

Abstract: The present disclosure is directed to a bioresorbable ceramic composition having a plurality of biocompatible ceramic granules, each of the granules having a coating of a plurality of calcium containing particles, where at least a portion of the particles are bound to at least a portion of an outer surface of each of the granules, and further where the composition is flowable in a dry state. The present disclosure is also directed to a three dimensional scaffold for bone repair that includes the bioresorbable composition, which upon implantation to a locus of repair defines an interconnected pore network between outer walls of the coated granules of the composition. Finally, the present disclosure is directed to methods of forming both the bioresorbable ceramic composition and the three-dimensional ceramic scaffold.

Abstract: Methods and devices for tissue remodeling and repair of collagenous tissues, including tendons, ligaments, and bone, as well as scalable connective tissue manufacturing, are provided. Collagen fibers are assembled by extensional strain-induced flow crystallization of collagen monomers. Extensional strain also drives the fusion of already formed short collagen fibrils to produce long-range, continuous fibers. Wearable devices for controlled tissue remodeling and wound healing deliver a tissue remodeling solution to a tissue repair site. The remodeling solution, together with appropriate application of strain to the tissue remodeling site, accelerate healing, prevent injury, and reduce scar formation.

Abstract: A coating for a roughened metal surface of an implantable medical device includes a poly(ethylene glycol) disposed on at least a portion of the roughened metal surface, wherein the poly(ethylene glycol) is covalently bonded directly to the roughened metal surface.

Abstract: The present invention involves implants suitable for surgical implantation into subjects. In some embodiments the implants comprise a biocompatible scaffold material and blood vessels containing engineered endothelial cells—such as E4ORF1+ engineered endothelial cells or engineered endothelial cells that express certain marker molecules. The present invention provides implants, methods for preparing such implants, and methods of treatment utilizing such implants.

Abstract: The present disclosure relates to cartilage repair compositions and methods for modifying the proteoglycan content of the compositions. Specifically, the methods relate to serum free, collagen free neocartilage made from chondrocytes that can be used for implants. Proteoglycans, such as aggrecan and sulfated glycosaminoglycan are used and the content modified using temperature changes.